Evidence map›Paper›PMID 30666127›Full record

ReviewOncoTargets and therapy2019

Diagnostic significance of miR-210 as a potential tumor biomarker of human cancer detection: an updated pooled analysis of 30 articles.

Song Feng, Anbang He, Deli Wang, Bin Kang

Abstract readReview
In one paragraph

Review in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Song FengDepartment of Bone and Joint Surgery, Peking University Shenzhen Hospital, Peking University Shenzhen, Shenzhen 518038, Guangdong, China, wangdelinavy@163.com; szkangbin_12@sina.com.
Anbang HeDepartment of Urology, Peking University First Hospital, The Institute of Urology, Peking University National Urological Cancer Centre, Beijing 100034, China.
Deli WangDepartment of Bone and Joint Surgery, Peking University Shenzhen Hospital, Peking University Shenzhen, Shenzhen 518038, Guangdong, China, wangdelinavy@163.com; szkangbin_12@sina.com.
Bin KangDepartment of Bone and Joint Surgery, Peking University Shenzhen Hospital, Peking University Shenzhen, Shenzhen 518038, Guangdong, China, wangdelinavy@163.com; szkangbin_12@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A large number of studies have explored the diagnostic value of miR-210 as a potential diagnostic cancer biomarker to detect various cancers in patients. However, the results of its diagnostic accuracy and reliability in individual studies are still inconsistent. Therefore, we conducted this updated pooled analysis to derive a more reliable conclusion of the overall accuracy of miR-210 in cancer detection and diagnosis. A comprehensive literature search was performed using the PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and Wanfang databases. The quality of all eligible studies was scored according to Quality Assessment of Diagnostic Accuracy Studies-2 guidelines. The bivariate mixed model was applied to pooled sensitivity, specificity, likelihood ratios, and diagnostic ORs. The summary receiver operator characteristic (SROC) curve and the hierarchical SROC models were used to check overall diagnostic performance. Thirty articles with 2,304 patients and 1,673 controls were included in this study. The pooled parameters calculated from all studies are as follows: sensitivity -0.74 (95% CI: 0.68-0.79), specificity -0.79 (95% CI: 0.74-0.83), positive likelihood ratio -3.57 (95% CI: 2.85-4.47), negative likelihood ratio -0.32 (95% CI: 0.26-0.40), diagnostic OR -10.98 (95% CI: 7.55-15.98), SROC -0.84 (95% CI: 0.80-0.87). All of these results revealed that miR-210 had relatively moderate accuracy in distinguishing patients with various cancers from all other individuals. However, well-designed prospective studies with large sample sizes using different groups of the population are urgently warranted to confirm our findings.

Indexed as

biomarkercancerdiagnosismeta-analysismicroRNA-210ROC

Identifiers

PMID30666127
PMCPMC6331190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.